Detalles de la búsqueda
1.
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option.
Blood
; 142(1): 73-89, 2023 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37018663
2.
Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions.
Eur J Haematol
; 111(4): 644-654, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37503797
3.
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.
Am J Hematol
; 97(4): 421-430, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35015312
4.
Mental health and psychosocial consequences linked to radiation emergencies-increasingly recognised concerns.
J Radiol Prot
; 42(3)2022 07 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35767945
5.
The acute radiation syndrome-need for updated medical guidelines.
J Radiol Prot
; 42(1)2022 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35021163
6.
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
Br J Haematol
; 193(5): 915-921, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33782950
7.
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.
Eur J Haematol
; 107(6): 617-623, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34418168
8.
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.
Blood
; 129(17): 2384-2394, 2017 04 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-28122740
9.
Interferon γ is a strong, STAT1-dependent direct inducer of BCL6 expression in multiple myeloma cells.
Biochem Biophys Res Commun
; 498(3): 502-508, 2018 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29510136
10.
Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34+CD38- stem and progenitor cells in chronic myeloid leukemia.
Biochem Biophys Res Commun
; 490(2): 378-384, 2017 08 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-28623130
11.
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib.
Haematologica
; 102(8): 1361-1367, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28522574
12.
The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia.
Eur J Haematol
; 98(4): 398-406, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28009456
13.
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register.
Eur J Haematol
; 98(1): 57-66, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27428357
14.
Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.
Ann Intern Med
; 165(3): 161-6, 2016 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27295519
15.
To be (prepared) or not to be-that is hardly the question.
J Radiol Prot
; 42(3)2022 07 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35767967
16.
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lancet Oncol
; 17(5): 612-21, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27083332
17.
Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
Eur J Haematol
; 97(4): 387-92, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26833713
18.
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.
Biol Blood Marrow Transplant
; 21(3): 559-64, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25536215
19.
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
Br J Haematol
; 169(5): 683-8, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25817799
20.
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.
Blood
; 121(24): 4854-60, 2013 Jun 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-23591789